Cooperative Agreement NU2GGH002359

Award Date 9/30/21
Completion Date 9/29/26
Dollars Obligated $4M
Funding Federal Agency
Center for Global Health
Awarding Federal Agency
Office of Financial Resources
Federal Grant Program
93.067
Assistance Type
Cooperative Agreement
Place of Performance
Uganda
Similar Awards
This Project Grant award in the amount of $431,712, funded by the National Institute of Allergy and Infectious Diseases under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to improve HIV testing among children under five in rural Uganda. The primary goal is to engage with traditional healers to facilitate HIV counseling and testing via oral swab antigen tests for this vulnerable pediatric population. The award supports two key activities: 1) determining barriers and...
This Project Grant awarded by the National Institute of Child Health and Human Development (NICHD) under CFDA 93.865 - Child Health and Human Development Extramural Research, will provide $259,818 to the University of North Carolina at Chapel Hill to characterize adherence and estimate per-protocol effects for pediatric use of the antiretroviral drug dolutegravir. The objectives are to (1) identify barriers to pediatric dolutegravir combination therapy adherence, and (2) estimate per-protocol...
This federal Project Grant award from the National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research program (CFDA 93.865), is providing $573,475 to The Botswana Harvard Health Partnership (BHP) to conduct a randomized trial evaluating the effect of integrating sexually transmitted infection (STI) testing with expanded pre-exposure prophylaxis (PrEP) options on PrEP use among pregnant women in Botswana. The study aims to...
This federal Project Grant award of $756,077, provided by the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865), supports a 5-year research study on the long-term immunologic, cardiovascular, metabolic, and neurocognitive consequences of inflammation in children with perinatal HIV in sub-Saharan Africa. The primary objectives are to assess the durability of inflammation and immune...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $1,314,701.00 to support research focused on optimizing dolutegravir-based antiretroviral therapy (ART) in children and adolescents. The primary award recipient is the University of Florida, which will oversee the overall research project. The project includes sub-awards to Kwame Nkrumah University of Science...
This federal Project Grant award under the Child Health and Human Development Extramural Research program (CFDA 93.865) at the National Institute of Child Health and Human Development will support research on the impact of dolutegravir (DTG)-based antiretroviral therapy (ART) regimens on appetite regulation and weight management in postpartum women living with HIV and their HIV-exposed uninfected (HEU) infants. The total funding amount is $262,105 for the project period from August 6, 2024 to...
This federal Project Grant award of $709,872 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to develop and pilot test a couple-based intervention to address perinatal depression and improve adherence to prevention of mother-to-child transmission (PMTCT) of HIV in Malawi. The key objectives are to: 1) develop a couple-based intervention using problem-solving therapy and content on couple...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $153,912 to the University of Ghana Medical Centre to conduct research on the pharmacokinetics and pharmacogenomics of dolutegravir-based antiretroviral therapy in young people living with HIV in Ghana. The key objectives of this research project are to: 1) Determine rates of dolutegravir-based antiretroviral therapy...
This Project Grant award of $743,488.00 from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), under CFDA Program 93.865 Child Health and Human Development Extramural Research, aims to examine the mechanisms and optimization of malaria chemoprevention strategies to improve birth outcomes in Africa. The research objectives are to: 1) characterize the mechanisms mediating the effects of sulfadoxine-pyrimethamine (SP) and dihydroartemisinin-piperaquine...
The National Institute of Child Health and Human Development (NICHD) awarded a $158,000 Project Grant under the Child Health and Human Development Extramural Research program (CFDA 93.865) to Rush University Medical Center. The grant, awarded on September 6, 2023, will fund a study to determine the long-term effects of in-utero and lactational exposure to dolutegravir-based combination antiretroviral therapy (CART) on bone and fat tissues. The research aims to address a critical clinical...

HOSPITAL BASED BIRTH DEFECTS SURVEILLANCE IN KAMPALA - COMPREHENSIVE RELIABLE DATA ON THE BASELINE PREVALENCE AND RISK OF BIRTH DEFECTS IN RESOURCE-LIMITED COUNTRIES IS RARE OR NON-EXISTENT. CONCERNS HAVE BEEN RAISED ABOUT THE POSSIBILITY OF HIV ANTIRETROVIRAL THERAPY (ART) AT CONCEPTION OR EARLY PREGNANCY HAVING AN INCREASED RISK OF ADVERSE BIRTH OUTCOMES, INCLUDING BIRTH DEFECTS. HOWEVER, INTRODUCTION OF NEW DRUGS TO MANAGE HIV AND OTHER DISEASES DURING PREGNANCY CONTINUES. WITHOUT A SURVEILLANCE SYSTEM, IT IS DIFFICULT TO HAVE AN EFFECTIVE MEANS TO EVALUATE THE ASSOCIATION OF THESE NEW MEDICATIONS AND ADVERSE BIRTH OUTCOMES. THE PURPOSE OF THIS BIRTH DEFECT SURVEILLANCE SYSTEM IS TO CONTINUE TO PROVIDE BACKGROUND PREVALENCE RATES OF MAJOR EXTERNAL BIRTH DEFECT AND PROVIDE A MECHANISM TO DETERMINE IF THE MATERNAL USE OF DOLUTEGRAVIR, COTRIMOXAZOLE, AND OTHER MEDICATIONS IN EARLY PREGNANCY ARE ASSOCIATED WITH A HIGHER RISK OF BIRTH DEFECTS IN NEWBORNS AND OTHER ADVERSE PREGNANCY OUTCOMES; ESPECIALLY AS THEY TRANSITION TO DOLUTEGRAVIR AS THE PREFERRED ART REGIMEN INCREASES, TO PREVENT MOTHER TO CHILD TRANSMISSION OF HIV. THIS SURVEILLANCE PROJECT ALSO PROVIDES A UNIQUE OPPORTUNITY TO IMPROVE THE SURVIVAL OF NEWBORNS WITH BIRTH DEFECTS THROUGH STRENGTHENING REFERRAL LINKAGES AND MAKING PARTNERSHIPS WITH HEALTH FACILITIES/ORGANIZATIONS THAT PROVIDE CARE AND SUPPORT FOR AFFECTED CHILDREN AND THEIR FAMILIES. OVER THE FIVE-YEAR PERIOD OF THIS PROJECT, THE SURVEILLANCE TEAM WILL WORK IN COLLABORATION WITH UGANDA MINISTRY OF HEALTH (MOH) AND KEY STAKEHOLDERS TO EXPAND THE SURVEILLANCE TO OTHER REGIONS IN THE COUNTRY AND INCORPORATE BIRTH DEFECT SURVEILLANCE INTO THE NATIONAL SYSTEM TO ENSURE SUSTAINABILITY AFTER THE END OF THE PROJECT. THE LONG-TERM OUTCOMES OF THIS PROJECT INCLUDE A SUSTAINABLE BIRTH DEFECT SURVEILLANCE SYSTEM INTEGRATED WITHIN UGANDA?S PUBLIC HEALTH SYSTEM; EVIDENCE OF CURRENT BIRTH DEFECT PREVALENCE AND COMMON RISK FACTORS, WHICH WILL GUIDE POLICY ON BIRTH DEFECT PREVENTION AND IMPROVE CARE FOR NEWBORNS WITH BIRTH DEFECTS. FURTHERMORE, FINDINGS FROM THIS PROJECT WILL INFORM MOH, WHO, AND PEPFAR ON USE OF SPECIFIC HIV, TB, AND OTHER MEDICATIONS DURING PREGNANCY.

Posted 8/19/21, 12:00 AM